Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Arrowhead Pharmaceuticals, Inc.”

89 pharma patents match "Arrowhead Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 89
Index total 30,257
Page 1 / 4

Quick answer

This filtered view shows 89 pharmaceutical patents matching "Arrowhead Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

89 results for “Arrowhead Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12378558

    RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  2. US 12365899

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  3. US 12365897

    RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  4. US 12221610

    RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  5. US 12188017

    Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  6. US 12173086

    Alpha-v beta-6 integrin ligands and uses thereof

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  7. US 12116573

    Targeting ligands for therapeutic compounds

    Arrowhead Pharmaceuticals, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  8. US 12110492

    RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  9. US 12091661

    Organic compositions to treat HSF1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  10. US 12065458

    Trialkyne linking agents and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  11. US 12054718

    RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  12. US 11920134

    Compositions and methods for inhibiting expression of RRM2 genes

    Arrowhead Pharmaceuticals, Inc. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  13. US 11912997

    RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  14. US 11884920

    Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  15. US 11845937

    RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  16. US 11840688

    Compositions and methods for inhibiting gene expression of Hif2alpha

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  17. US 11629349

    RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Apr 18, 2023 · Expires Apr 13, 2043

    granted
  18. US 11597701

    Integrin ligands and uses thereof

    Arrowhead Pharmaceuticals, Inc. · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  19. US 11590156

    RNAi agents for hepatitis B virus infection

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  20. US 11549112

    RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  21. US 11534453

    RNAi therapy for hepatitis B virus infection

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted
  22. US 11517584

    RNAi agents for Hepatitis B virus infection

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  23. US 11492624

    RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1

    Arrowhead Pharmaceuticals, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  24. US 11384355

    Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted